search button

Upregulation of microRNA‑492 induced by epigenetic drug treatment inhibits the malignant phenotype of clear cell renal cell carcinoma in vitro

  • Authors:
    • Aibing Wu
    • Kunpeng Wu
    • Mingchun Li
    • Lingli Bao
    • Xiang Shen
    • Shunjun Li
    • Jinmei Li
    • Zhixiong Yang

  • View Affiliations

  • Published online on: March 26, 2015     https://doi.org/10.3892/mmr.2015.3550
  • Pages: 1413-1420
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common type of cancer of the renal parenchyma. MicroRNAs (miRNAs) are non‑coding RNAs of ~22 nucleotides in length, which function as post‑transcriptional regulators. Recently, the downregulation of miRNA (miR)‑492 was observed to be associated with ccRCC; however, the molecular mechanism by which miR‑492 inhibited ccRCC remained to be elucidated. In the present study, it was demonstrated that miR‑492 was markedly downregulated in ccRCC tissues when compared with adjacent normal tissues, as determined by reverse transcription‑quantitative poymerase chain reaction (PCR). This downregulation was predominantly due to the hypermethylation of the CpG island of the miR‑492 promoter, which was detected by methylation specific PCR and bisulfite genomic sequencing PCR, and was shown to inhibit miR‑492 transcription. Through the use of a DNA demethylation agent, 5‑aza‑2'‑deoxycytidine or the histone deacetylase inhibitor 4‑phenylbutyric acid, the expression level of miR‑492 was significantly upregulated in ccRCC cells, which further inhibited cell proliferation and invasion, while promoting cell apoptosis and adhesion. In conclusion, the present study provided novel insights into the potential mechanisms involved in ccRCC and it is hypothesized that miR‑492 may become a promising therapeutic agent in the treatment of ccRCC.
View Figures
View References

Related Articles

Journal Cover

July-2015
Volume 12 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 3.4
  • Ranked Medicine Research and Experimental
    (total number of cites)
  • CiteScore: 6.9
  • CiteScore Rank: Q2: #98/328 Biochemistry, Genetics and Molecular Biology
  • Source Normalized Impact per Paper (SNIP): 0.721
  • SCImago Journal Rank (SJR): 0.65
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Wu A, Wu K, Li M, Bao L, Shen X, Li S, Li J and Yang Z: Upregulation of microRNA‑492 induced by epigenetic drug treatment inhibits the malignant phenotype of clear cell renal cell carcinoma in vitro. Mol Med Rep 12: 1413-1420, 2015
APA
Wu, A., Wu, K., Li, M., Bao, L., Shen, X., Li, S. ... Yang, Z. (2015). Upregulation of microRNA‑492 induced by epigenetic drug treatment inhibits the malignant phenotype of clear cell renal cell carcinoma in vitro. Molecular Medicine Reports, 12, 1413-1420. https://doi.org/10.3892/mmr.2015.3550
MLA
Wu, A., Wu, K., Li, M., Bao, L., Shen, X., Li, S., Li, J., Yang, Z."Upregulation of microRNA‑492 induced by epigenetic drug treatment inhibits the malignant phenotype of clear cell renal cell carcinoma in vitro". Molecular Medicine Reports 12.1 (2015): 1413-1420.
Chicago
Wu, A., Wu, K., Li, M., Bao, L., Shen, X., Li, S., Li, J., Yang, Z."Upregulation of microRNA‑492 induced by epigenetic drug treatment inhibits the malignant phenotype of clear cell renal cell carcinoma in vitro". Molecular Medicine Reports 12, no. 1 (2015): 1413-1420. https://doi.org/10.3892/mmr.2015.3550